Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 18/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000680 | 0.86 | EPHX2 (0.64) | EPHX2MAPTSMN1; SMN2 | |
| SCHEMBL14222742 | 0.84 | GAA (0.53) | GAAEPHX2ALDH1A1MAPTHPGD | |
| SCHEMBL4927703 | 0.78 | EPHX2 (0.77) | EPHX2ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL12932180 | 0.75 | EPHX2 (1.00) | EPHX2ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL14222737 | 0.75 | EPHX2 (0.48) | EPHX2ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL6568488 | 0.75 | EPHX2 (1.00) | EPHX2ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL4927278 | 0.74 | EPHX2 (0.61) | EPHX2ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL3998620 | 0.73 | GAA (0.63) | GAAEPHX2ALDH1A1MAPTHPGD | |
| SCHEMBL12932201 | 0.73 | EPHX2 (1.00) | EPHX2ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL3762758 | 0.73 | GAA (0.70) | GAAALDH1A1MAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066642-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-10 | — | — | EP | claimed |
| WO-2008039794-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20080076770-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-03-27 | — | — | US | claimed |
| US-20080076770-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076770-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076770-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076770-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | GAA 1387/4885EPHX2 2/4885ALDH1A1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.